初始出血前使用抗血小板药物的动脉瘤性蛛网膜下腔出血患者的管理:一项国际调查
该调查向2017年10月1日至5日在意大利威尼斯举行的欧洲神经外科协会年会参会者发放11道关于初始出血前使用抗血小板药物的动脉瘤性蛛网膜下腔出血患者管理选择题,回收258份完整问卷(54%)。约80%的问卷中神经外科和神经内科负责急性管理,15%由重症监护病房负责,32%有科室指南;65%的应答者入院时总是停用抗血小板药物,4.3%总是输注血小板。存在指南时神经专科医生更常考虑输注血小板(83% vs 65%,P=0.02)。
要点
- 约80%的问卷中神经外科和神经内科负责急性管理,15%由重症监护病房负责。
- 32%的应答者所在科室有指南,65%的应答者入院时总是停用抗血小板药物。
- 存在指南时神经专科医生更常考虑输注血小板(83% vs 65%,P=0.02)。
核心结论
- 该调查显示,对于初始出血前使用抗血小板药物的动脉瘤性蛛网膜下腔出血患者,管理存在显著差异。
- 作者强调需要制定基于证据的指南来管理初始出血前使用抗血小板药物的动脉瘤性蛛网膜下腔出血患者。
研究设计与样本
- 向2017年10月1日至5日在意大利威尼斯举行的欧洲神经外科协会年会参会者发放匿名调查问卷,共11道关于初始出血前使用抗血小板药物的动脉瘤性蛛网膜下腔出血患者管理的选择题。
- 共回收258份完整问卷(54%)。
主要发现
- 约80%的问卷中神经外科和神经内科负责动脉瘤性蛛网膜下腔出血患者的急性管理,15%由重症监护病房负责。
- 32%的应答者所在科室有指南。
- 65%的应答者入院时总是停用抗血小板药物,4.3%总是输注血小板。
- 存在指南时,神经专科医生更常考虑输注血小板(83% vs 65%,P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The case fatality in aneurysmal subarachnoid hemorrhage (aSAH) is 50% because of the initial hemorrhage or subsequent complications, such as aneurysmal rebleed or delayed cerebral ischemia. One factor that might influence the initial brain damage or subsequent complications is the use of antiplatelet medication before the initial hemorrhage. The goal of this survey was to assess the different management options of patients with aSAH with antiplatelet use before the initial hemorrhage. METHODS: An anonymous survey of 11 multiple choice questions about management of patients with aSAH with antiplatelet use before the initial hemorrhage was distributed to the international panel of attendees of the European Association of Neurosurgical Societies annual meeting in Venice, Italy, October 1-5, 2017. RESULTS: A total of 258 completed surveys (54%) were returned. In about 80% of the surveys, the departments of neurosurgery and neurology were responsible for acute management of patients with aSAH, whereas in 15% the intensive care unit was responsible. Department guidelines were present in 32%. In 65%, the responders always stopped the antiplatelet agent at admission, and in 4.3% thrombocytes are always transfused. When a guideline is present, the neurospecialists consider thrombocyte transfusion more often (83% vs. 65%, respectively; P = 0.02). CONCLUSIONS: Our survey among mainly European neurosurgeons shows that there is a significant variability in the management of patients with aSAH who have been using antiplatelets before the initial hemorrhage. These findings emphasize the importance of the development of evidence-based guidelines for management of patients with aSAH and antiplatelet use before the initial hemorrhage.
引用
- Sebök M, Keller E, van Niftrik CHB, et al. Management of Aneurysmal Subarachnoid Hemorrhage Patients with Antiplatelet Use Before the Initial Hemorrhage: An International Survey. World Neurosurg. 2018. PMID: 30149168. doi:10.1016/j.wneu.2018.08.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。